Pharmacopeia, Inc. (NASDAQ: PCOP), a clinical development stage biopharmaceutical company, is focused on discovering and developing innovative small molecule therapeutics to attend to significant medical needs. The company’s broad portfolio of clinical and preclinical candidates are currently under development internally or with partners, including nine clinical compounds in Phase 2 or Phase 1 development. For further information, visit the Company’s web site at www.pcop.com.
- 17 years ago
QualityStocks
Pharmacopeia, Inc. (NASDAQ: PCOP)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Powering AI: Nicola Mining Inc.’s (TSX.V: NIM) (OTCQB: HUSIF) Copper Project Aligns with Data Center Surge
As artificial intelligence (“AI”) continues to revolutionize industries, the infrastructure supporting its growth has become…
-
Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Breaks Ground on REE Processing Facility, Pioneers Domestic Supply Chain
The company announced the groundbreaking of its Louisiana Strategic Metals Complex (“SMC”) in Alexandria. The…
-
NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100
The new FDA voucher program aims to speed approval of drugs aligned with national health…